menu
    • menu

    Company profile for Minerva Biotechnologies

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Minerva Biotechnologies is developing cancer immunotherapies and cancer drugs to target 80% of solid tumors and to prevent cancer metastasis. Our stem cell technology could transform the field of regenerative medicine. We discovered that cancer cells are healthy cells that are being reprogrammed back to a stem cell state. We can reverse the reprogramming and make cancer cells mature so that cancer growth is turned off. Th...
    Minerva Biotechnologies is developing cancer immunotherapies and cancer drugs to target 80% of solid tumors and to prevent cancer metastasis. Our stem cell technology could transform the field of regenerative medicine. We discovered that cancer cells are healthy cells that are being reprogrammed back to a stem cell state. We can reverse the reprogramming and make cancer cells mature so that cancer growth is turned off. This is a unique approach to curing cancer

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Minerva BiotechnologiesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    40 Bear Hill Road Waltham, MA 02451-1002
    Telephone
    Telephone
    781-487-0200 103
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.minervabio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Patient-Derived Stem Cells Advance Regenerative Medicine
    Patient-Derived Stem Cells Advance Regenerative Medicine

    25 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250625947341/en/Breakthrough-in-Patient-Derived-Stem-Cells-for-Therapeutic-Regenerative-Medicine

    BUSINESSWIRE
    25 Jun 2025
    Share Share
    Minerva CAR T Targets MUC1 To Overcome Tumor Exhaustion*
    Minerva CAR T Targets MUC1 To Overcome Tumor Exhaustion*

    02 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250602852577/en/Minerva-Biotechnologies---Overcoming-the-Solid-Tumor-Barrier-MUC1-Targeted-CAR-T-bearing-1XX-mutations-overcomes-exhaustion-and-enables-killing-of-low-antigen-expressing-cancer-cells

    BUSINESSWIRE
    02 Jun 2025
    Share Share
    Minerva Biotechnologies Gets FDA Approval of IND for a MUC1*-CAR-1XX
    Minerva Biotechnologies Gets FDA Approval of IND for a MUC1*-CAR-1XX

    09 Jan 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230109005010/en

    BUSINESSWIRE
    09 Jan 2023
    Share Share
    Minerva Begins 1st-In-Human Phase I/II Trial of MUC1 star Targeting CAR T
    Minerva Begins 1st-In-Human Phase I/II Trial of MUC1 star Targeting CAR T

    01 Feb 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220201005200/en

    BUSINESSWIRE
    01 Feb 2022
    Share Share
    Minerva Neurosciences Reports Second Quarter 2021 Financial Results
    Minerva Neurosciences Reports Second Quarter 2021 Financial Results

    02 Aug 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/08/02/2272736/32445/en/Minerva-Neurosciences-Reports-Second-Quarter-2021-Financial-Results-and-Business-Updates.html

    GLOBENEWSWIRE
    02 Aug 2021
    Share Share
    Minerva Surgical Issues Update on ?U.S. Supreme Court Ruling
    Minerva Surgical Issues Update on ?U.S. Supreme Court Ruling

    30 Jun 2021

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/minerva-surgical-issues-update-on-us-supreme-court-ruling-on-assignors-estoppel-301323098.html

    PR NEWSWIRE
    30 Jun 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search